Skip to main content
. 2023 May 29;37(4):1348–1357. doi: 10.1111/jvim.16741

TABLE 1.

Baseline characteristics of the study populations (n = 38).

PHA CKD‐H CKD‐NH HTH ISH Healthy Reference interval
n 5 9 7 9 2 6
Age (years) 10 [10; 17] 15 [14; 17] 15 [8; 15] 16 [14; 17] 12 [9; 14] 8 [7; 9]
Urea (mmol/L) 10.0 [6.5; 15.0] 15.3 [12.0; 21.2] 12.5 [12.0; 26.0] 13.0 [8.0; 14.7] 11.0 [4.20; 17.9] 9.5 [5.8; 9.9] 6.7‐13.4
Creatinine (μmol/L) 128 [90; 177] 186 [168; 305] 168 [151; 186] 96 [84; 124] 97 [80; 115] 89 [80; 97] 46‐142
Urine specific gravity 1.030 [1.026; 1.040] 1.016 [1.015; 1.025] 1.015 [1.012; 1.018] 1.028 [1.018; 1.031] 1.030 [1.025; 1.035] 1.016 [1.012; 1.020] >1.035
Aldosterone (pmol/L) 2 914 [2.789‐4.600] 239 [189‐577] 353 [136‐1 371] 389 [264‐478] 344 [169‐519] 137 [128‐227] 14‐258
Plasma renin activity (pmol/L/h) 2123 [352; 10 377] 193 [160; 494] 2450 [778; 7080] 634 [575; 3296] 462 [351; 572] 578 [253; 906] Not determined yet
T4 (nmol/L) 25 [6; 56] 27 [25; 36] 16 [6; 23] 108 [77; 176] 32 [27; 37] 28 [23; 31] 15‐50
Sodium (mmol/L) 149 [145; 154] 157 [154; 158] 149 [145; 156] 152 [152; 153] 158 [157; 159] 155 [154; 157] 150‐165
Potassium (mmol/L) 2.4 [2.4; 2.8] 4.1 [3.9; 4.7] 4.4 [3.5; 4.7] 4.1 [4.1; 4.6] 4.0 [3.9; 4] 4.2 [4.1; 4.6] 3.6‐5.5
Blood pressure (oscillometry, mmHg) 220 [210; 220] 220 [200; 230] 140 [135; 150] 160 [140; 190] 240 [220; 260] 138 [130; 140] 110‐160

Note: Results are presented as medians [1st quartile; 3rd quartile].

Abbreviations: CKD‐H and CKD‐NH, hypertensive and non‐hypertensive chronic kidney disease; HTH, hyperthyroidism; ISH, idiopathic systemic arterial hypertension; PHA, primary hyperaldosteronism.